-
Electronic (PDF)
-
Site License
-
Enterprisewide
Solid Tumors - Pipeline Review, Q1 2011
Global Markets Direct, January 2011, Pages: 289
Solid Tumors - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'Solid Tumors - Pipeline Review, Q1 2011', provides an overview of the Solid Tumors therapeutic pipeline. This report provides information on the therapeutic development for Solid Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Solid Tumors. 'Solid Tumors - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- A snapshot of the global therapeutic scenario for Solid Tumors.
- A review of the Solid Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Solid Tumors pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Solid Tumors.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Solid Tumors pipeline depth and focus of Solid Tumors therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Solid Tumors Overview
Therapeutics Development
An Overview of Pipeline Products for Solid Tumors
Solid Tumors Therapeutics under Development by Companies
Solid Tumors Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Solid Tumors Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Abraxis BioScience, Inc.
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Abbott Laboratories
Biogen Idec Inc.
Shionogi & Co., Ltd.
Amgen Inc.
Sanofi-Aventis
Adherex Technologies Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Seattle Genetics, Inc.
Tekmira Pharmaceuticals Corp.
Nektar Therapeutics
Antigenics, Inc.
Gilead Sciences, Inc.
Biotest AG
Merck & Co., Inc.
AbGenomics International, Inc.
Cangene Corporation
Oxford BioMedica plc
Micromet, Inc.
Infinity Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Albany Molecular Research, Inc.
Plexxikon Inc.
NeoPharm, Inc.
BioLineRx, Ltd.
YM BioSciences Inc.
Symphogen A/S
Light Sciences Oncology, Inc.
Ipsen S.A.
MediGene AG
Prolexys Pharmaceuticals, Inc.
Bio-Path Holdings, Inc.
Ambrilia Biopharma Inc.
Ark Therapeutics Group plc
A.P. Pharma, Inc.
Kereos, Inc.
ZIOPHARM Oncology, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Astellas Pharma Inc.
Cephalon, Inc.
Chong Kun Dang Pharmaceutical
Eisai Co., Ltd.
Genta Incorporated
GTC Biotherapeutics, Inc.
Human Genome Sciences, Inc.
ImmunoGen, Inc.
Mitsubishi Tanabe Pharma Corporation
Nippon Kayaku Co., Ltd.
Pfizer Inc.
Rigel Pharmaceuticals, Inc.
Sigma-Tau S.p.A.
Sunesis Pharmaceuticals, Inc.
SuperGen, Inc.
Yakult Honsha Co., Ltd.
Cell Therapeutics, Inc.
Genmab A/S
Progenics Pharmaceuticals, Inc.
Santaris Pharma A/S
Silence Therapeutics plc.
Calando Pharmaceuticals, Inc.
Exelixis, Inc.
Aduro BioTech
Menarini Group
Astex Therapeutics Limited
Cyclacel Pharmaceuticals Inc.
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Bayer AG
Geron Corporation
MannKind Corporation
Halozyme Therapeutics
Merck KGaA
Access Pharmaceuticals, Inc.
4SC AG
EntreMed, Inc.
EpiCept Corporation
Genesis Research and Development Corporation Ltd.
Hana Biosciences, Inc.
Celldex Therapeutics, Inc.
Momenta Pharmaceuticals, Inc.
Anavex Life Sciences Corp.
AEterna Zentaris Inc.
Ariad Pharmaceuticals, Inc.
Lorus Therapeutics Inc
Lpath, Inc.
MediciNova, Inc.
MethylGene Inc
Bionomics Limited
Northwest Biotherapeutics, Inc.
Callisto Pharmaceuticals, Inc.
Novogen Limited
ChemGenex Pharmaceuticals Limited
Circadian Technologies Limited
Oncothyreon Inc
OXiGENE, Inc.
Patrys Limited
Peregrine Pharmaceuticals, Inc.
Curis, Inc.
ARQULE, INC
ADVENTRX Pharmaceuticals
Alnylam Pharmaceuticals, Inc
Cytokinetics, Inc
TopoTarget A/S
Mundipharma International Limited
VioQuest Pharmaceuticals, Inc.
Poniard Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Oncogenex Pharmaceuticals, Inc.
Dendreon Corporation
Array BioPharma Inc.
Thallion Pharmaceuticals Inc.
Transgene SA
Progen Pharmaceuticals Limited
Pro-Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Clavis Pharma ASA
Protox Therapeutics Inc.
Sinobiomed, Inc.
Rexahn Pharmaceuticals, Inc.
Piramal Life Sciences Limited
SymBio Pharmaceuticals Limited
Baylor College of Medicine
Morphotek, Inc.
Spectrum Pharmaceuticals, Inc.
Affitech A/S
Debiopharm Group
Chroma Therapeutics Ltd.
Colby Pharmaceutical Company
Wilex AG
Ambit Biosciences Corporation
GANYMED Pharmaceuticals AG
Philogen S.p.A.
Antisoma Research Limited
Acceleron Pharma, Inc.
Pieris AG
Nerviano Medical Sciences S.r.l.
BioMAS Ltd.
Cadila Pharmaceuticals Ltd.
Hutchison MediPharma Limited
ERYtech Pharma
Calistoga Pharmaceuticals, Inc.
MAT Biopharma
Apogenix GmbH
BioNumerik Pharmaceuticals, Inc.
Aegera Therapeutics Inc.
EnGeneIC Ltd
Angiogene Pharmaceuticals Ltd.
GenSpera, Inc.
Ascenta Therapeutics, Inc.
Phoenix Biotechnology, Inc.
Coronado Biosciences, Inc.
Cerulean Pharma, Inc.
MacroGenics, Inc.
Arno Therapeutics, Inc.
ACT Biotech, Inc.
OncoMed Pharmaceuticals, Inc.
TetraLogic Pharmaceuticals
Unibioscreen S.A.
Five Prime Therapeutics, Inc.
Vaccinex, Inc.
Azaya Therapeutics, Inc.
Semafore Pharmaceuticals, Inc.
CanBas Co., Ltd.
S-BIO Pte Ltd
IC-MedTech, Inc.
Merrimack Pharmaceuticals, Inc.
Spirogen Ltd.
Conatus Pharmaceuticals Inc.
Deciphera Pharmaceuticals, LLC
Mersana Therapeutics, Inc.
Reata Pharmaceuticals, Inc.
Vascular Biogenics Ltd.
Jennerex Biotherapeutics, Inc.
Stemline Therapeutics, Inc.
Endocyte, Inc.
Proacta, Inc.
Cornerstone Pharmaceuticals, Inc.
AndroScience Corporation
Onconova Therapeutics, Inc
MolMed S.p.A.
Pharminox Limited
Gemin X Pharmaceuticals
Intellikine, Inc.
Intrexon Corporation
Syndax Pharmaceuticals, Inc.
NOXXON Pharma AG
NovaLead Pharma Pvt. Ltd.
Esperance Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
Transtech Pharma, Inc.
Y's Therapeutics Co., Ltd.
Expression Genetics, Inc.
Xencor, Inc.
ImmunoVaccine Technologies Inc.
Welichem Biotech Inc.
Oncolys BioPharma Inc.
Concordia Pharmaceuticals
HENKAN Pharmaceutical Co., Ltd.
BIND Biosciences, Inc.
NewLink Genetics Corporation
Tragara Pharmaceuticals, Inc.
Taiwan Liposome Company
Drais Pharmaceuticals, Inc.
PharmaMar, S.A.
Kiadis Pharma B.V.
Quintessence Biosciences, Inc.
VentiRx Pharmaceuticals, Inc.
AB Science
Adamis Pharmaceuticals Corporation
Tigris Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc.
Nereus Pharmaceuticals, Inc.
Viventia Biotechnologies Inc.
AVEO Pharmaceuticals, Inc.
Lytix Biopharma AS
Kringle Pharma, Inc.
TRACON Pharmaceuticals, Inc.
AstraZeneca AB
Advanced Cancer Therapeutics
Clovis Oncology, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
Targa Therapeutics Corp.
Pepscan Therapeutics
Taxolog, Inc.
Almac Discovery Ltd.
Medical Enzymes AG
Mebiopharm Co., Ltd.
IkerChem S.L.
Agennix AG
ImQuest Life Sciences
Gradalis Inc.
Accelerated Community Oncology Research Network, Inc.
Centocor Research and Development
Universities/Institutes Involved in Solid Tumors Therapeutics Development
Solid Tumors Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
APF530 + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-582664 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carfilzomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eniluracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Etheophazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Exelbine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OSI-906 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prodrax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Alpha-Lipoic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
anti-thymocyte globulin + busulfan + carboplatin + cyclophosphamide + etoposide + fludarabine phosphate + melphalan + thiotepa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Cisplatin + Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cefazolin Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Total-Body Irradiation + Autologous Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyproheptadine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dactinomycin + carboplatin + cyclophosphamide + epirubicin hydrochloride + etoposide + ifosfamide + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethason + Metoclopramide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Dronabinol + Palonosetron hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Gabapentin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Granisetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone + granisetron hydrochloride + metoclopramide hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lamotrigine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levofloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
levofloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
memantine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
naloxone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
octreotide acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ondansetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxandrolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sertraline hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Solid Tumors - Featured News
Jan 04, 2011: Vaccinex Starts Clinical Trial Of VX15 In Patients With Advanced Solid Tumors
Dec 22, 2010: Tekmira Initiates TKM-PLK1 Phase I Human Clinical Trial
Dec 20, 2010: Ambit Biosciences Initiates Phase I Clinical Trials For AC480
Dec 20, 2010: Rexahn Receives Patent In Japan For RX-0047
Dec 15, 2010: Abbott initiates ABT-806 Phase I trial in EGFR Expressing Tumors
Dec 15, 2010: Enzon Begins Phase I Study Of EZN-2968 In Collaboration With National Cancer Institute
Dec 06, 2010: ArQule Enrolls First Patient In Phase I Trial Of ARQ 736
Nov 19, 2010: Acceleron Reports Interim Findings From ACE-041 Phase I Study
Nov 19, 2010: ImmunoGen Presents Phase I Data Of IMGN388 At EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
Nov 19, 2010: ZIOPHARM Presents New Darinaparsin Preclinical Data At EORTC-NCI-AACR Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Solid Tumors, 2011
Products under Development for Solid Tumors – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
Bristol-Myers Squibb Company, 2011
Genzyme Corporation, 2011
Abraxis BioScience, Inc., 2011
Johnson & Johnson, 2011
Boehringer Ingelheim GmbH, 2011
F. Hoffmann-La Roche Ltd., 2011
Kyowa Hakko Kirin Co., Ltd., 2011
Abbott Laboratories, 2011
Biogen Idec Inc., 2011
Shionogi & Co., Ltd., 2011
Amgen Inc., 2011
Sanofi-Aventis, 2011
Adherex Technologies Inc., 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
GlaxoSmithKline plc, 2011
Seattle Genetics, Inc., 2011
Tekmira Pharmaceuticals Corp., 2011
Nektar Therapeutics, 2011
Antigenics, Inc., 2011
Gilead Sciences, Inc., 2011
Biotest AG, 2011
Merck & Co., Inc., 2011
AbGenomics International, Inc., 2011
Cangene Corporation, 2011
Oxford BioMedica plc, 2011
Micromet, Inc., 2011
Infinity Pharmaceuticals, Inc., 2011
Takeda Pharmaceutical Company Limited, 2011
Albany Molecular Research, Inc., 2011
Plexxikon Inc., 2011
NeoPharm, Inc., 2011
BioLineRx, Ltd., 2011
YM BioSciences Inc., 2011
Symphogen A/S, 2011
Light Sciences Oncology, Inc., 2011
Ipsen S.A., 2011
MediGene AG, 2011
Prolexys Pharmaceuticals, Inc., 2011
Bio-Path Holdings, Inc., 2011
Ambrilia Biopharma Inc., 2011
Ark Therapeutics Group plc, 2011
A.P. Pharma, Inc., 2011
Kereos, Inc., 2011
ZIOPHARM Oncology, Inc., 2011
Millennium Pharmaceuticals, Inc., 2011
Novartis AG, 2011
Astellas Pharma Inc., 2011
Cephalon, Inc., 2011
Chong Kun Dang Pharmaceutical, 2011
Eisai Co., Ltd., 2011
Genta Incorporated, 2011
GTC Biotherapeutics, Inc., 2011
Human Genome Sciences, Inc., 2011
ImmunoGen, Inc., 2011
Mitsubishi Tanabe Pharma Corporation, 2011
Nippon Kayaku Co., Ltd., 2011
Pfizer Inc., 2011
Rigel Pharmaceuticals, Inc., 2011
Sigma-Tau S.p.A., 2011
Sunesis Pharmaceuticals, Inc., 2011
SuperGen, Inc., 2011
Yakult Honsha Co., Ltd., 2011
Cell Therapeutics, Inc., 2011
Genmab A/S, 2011
Progenics Pharmaceuticals, Inc., 2011
Santaris Pharma A/S, 2011
Silence Therapeutics plc., 2011
Calando Pharmaceuticals, Inc., 2011
Exelixis, Inc., 2011
Aduro BioTech, 2011
Menarini Group, 2011
Astex Therapeutics Limited, 2011
Cyclacel Pharmaceuticals Inc., 2011
Celgene Corporation, 2011
Onyx Pharmaceuticals, Inc., 2011
Bayer AG, 2011
Geron Corporation, 2011
MannKind Corporation, 2011
Halozyme Therapeutics, 2011
Merck KGaA, 2011
Access Pharmaceuticals, Inc., 2011
4SC AG, 2011
EntreMed, Inc., 2011
EpiCept Corporation, 2011
Genesis Research and Development Corporation Ltd., 2011
Hana Biosciences, Inc., 2011
Celldex Therapeutics, Inc., 2011
Momenta Pharmaceuticals, Inc., 2011
Anavex Life Sciences Corp., 2011
AEterna Zentaris Inc., 2011
Ariad Pharmaceuticals, Inc., 2011
Lorus Therapeutics Inc, 2011
Lpath, Inc., 2011
MediciNova, Inc., 2011
MethylGene Inc, 2011
Bionomics Limited, 2011
Northwest Biotherapeutics, Inc., 2011
Callisto Pharmaceuticals, Inc., 2011
Novogen Limited, 2011
ChemGenex Pharmaceuticals Limited, 2011
Circadian Technologies Limited, 2011
Oncothyreon Inc, 2011
OXiGENE, Inc., 2011
Patrys Limited, 2011
Peregrine Pharmaceuticals, Inc., 2011
Curis, Inc., 2011
ARQULE, INC, 2011
ADVENTRX Pharmaceuticals, 2011
Alnylam Pharmaceuticals, Inc, 2011
Cytokinetics, Inc, 2011
TopoTarget A/S, 2011
Mundipharma International Limited, 2011
VioQuest Pharmaceuticals, Inc., 2011
Poniard Pharmaceuticals, Inc., 2011
Regeneron Pharmaceuticals, Inc., 2011
Oncogenex Pharmaceuticals, Inc., 2011
Dendreon Corporation, 2011
Array BioPharma Inc., 2011
Thallion Pharmaceuticals Inc., 2011
Transgene SA, 2011
Progen Pharmaceuticals Limited, 2011
Pro-Pharmaceuticals, Inc., 2011
Threshold Pharmaceuticals, Inc., 2011
Synta Pharmaceuticals Corp., 2011
Clavis Pharma ASA, 2011
Protox Therapeutics Inc., 2011
Sinobiomed, Inc., 2011
Rexahn Pharmaceuticals, Inc., 2011
Piramal Life Sciences Limited, 2011
SymBio Pharmaceuticals Limited, 2011
Baylor College of Medicine, 2011
Morphotek, Inc., 2011
Spectrum Pharmaceuticals, Inc., 2011
Affitech A/S, 2011
Debiopharm Group, 2011
Chroma Therapeutics Ltd., 2011
Colby Pharmaceutical Company, 2011
Wilex AG, 2011
Ambit Biosciences Corporation, 2011
GANYMED Pharmaceuticals AG, 2011
Philogen S.p.A., 2011
Antisoma Research Limited, 2011
Acceleron Pharma, Inc., 2011
Pieris AG, 2011
Nerviano Medical Sciences S.r.l., 2011
BioMAS Ltd., 2011
Cadila Pharmaceuticals Ltd., 2011
Hutchison MediPharma Limited, 2011
ERYtech Pharma, 2011
Calistoga Pharmaceuticals, Inc., 2011
MAT Biopharma, 2011
Apogenix GmbH, 2011
BioNumerik Pharmaceuticals, Inc., 2011
Aegera Therapeutics Inc., 2011
EnGeneIC Ltd, 2011
Angiogene Pharmaceuticals Ltd., 2011
GenSpera, Inc., 2011
Ascenta Therapeutics, Inc., 2011
Phoenix Biotechnology, Inc., 2011
Coronado Biosciences, Inc., 2011
Cerulean Pharma, Inc., 2011
MacroGenics, Inc., 2011
Arno Therapeutics, Inc., 2011
ACT Biotech, Inc., 2011
OncoMed Pharmaceuticals, Inc., 2011
TetraLogic Pharmaceuticals, 2011
Unibioscreen S.A., 2011
Five Prime Therapeutics, Inc., 2011
Vaccinex, Inc., 2011
Azaya Therapeutics, Inc., 2011
Semafore Pharmaceuticals, Inc., 2011
CanBas Co., Ltd., 2011
S-BIO Pte Ltd, 2011
IC-MedTech, Inc., 2011
Merrimack Pharmaceuticals, Inc., 2011
Spirogen Ltd., 2011
Conatus Pharmaceuticals Inc., 2011
Deciphera Pharmaceuticals, LLC, 2011
Mersana Therapeutics, Inc., 2011
Reata Pharmaceuticals, Inc., 2011
Vascular Biogenics Ltd., 2011
Jennerex Biotherapeutics, Inc., 2011
Stemline Therapeutics, Inc., 2011
Endocyte, Inc., 2011
Proacta, Inc., 2011
Cornerstone Pharmaceuticals, Inc., 2011
AndroScience Corporation, 2011
Onconova Therapeutics, Inc, 2011
MolMed S.p.A., 2011
Pharminox Limited, 2011
Gemin X Pharmaceuticals, 2011
Intellikine, Inc., 2011
Intrexon Corporation, 2011
Syndax Pharmaceuticals, Inc., 2011
NOXXON Pharma AG, 2011
NovaLead Pharma Pvt. Ltd., 2011
Esperance Pharmaceuticals, Inc., 2011
Mirna Therapeutics, Inc., 2011
Transtech Pharma, Inc., 2011
Y's Therapeutics Co., Ltd., 2011
Expression Genetics, Inc., 2011
Xencor, Inc., 2011
ImmunoVaccine Technologies Inc., 2011
Welichem Biotech Inc., 2011
Oncolys BioPharma Inc., 2011
Concordia Pharmaceuticals, 2011
HENKAN Pharmaceutical Co., Ltd., 2011
BIND Biosciences, Inc., 2011
NewLink Genetics Corporation, 2011
Tragara Pharmaceuticals, Inc., 2011
Taiwan Liposome Company, 2011
Drais Pharmaceuticals, Inc., 2011
PharmaMar, S.A., 2011
Kiadis Pharma B.V., 2011
Quintessence Biosciences, Inc., 2011
VentiRx Pharmaceuticals, Inc., 2011
AB Science, 2011
Adamis Pharmaceuticals Corporation, 2011
Tigris Pharmaceuticals, Inc., 2011
Cylene Pharmaceuticals, Inc., 2011
Nereus Pharmaceuticals, Inc., 2011
Viventia Biotechnologies Inc., 2011
AVEO Pharmaceuticals, Inc., 2011
Lytix Biopharma AS, 2011
Kringle Pharma, Inc., 2011
TRACON Pharmaceuticals, Inc., 2011
AstraZeneca AB, 2011
Advanced Cancer Therapeutics, 2011
Clovis Oncology, Inc., 2011
Boehringer Ingelheim Pharmaceuticals, Inc., 2011
Targa Therapeutics Corp., 2011
Pepscan Therapeutics, 2011
Taxolog, Inc., 2011
Almac Discovery Ltd., 2011
Medical Enzymes AG, 2011
Mebiopharm Co., Ltd., 2011
IkerChem S.L., 2011
Agennix AG, 2011
ImQuest Life Sciences, 2011
Gradalis Inc., 2011
Accelerated Community Oncology Research Network, Inc., 2011
Centocor Research and Development, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products
List of Figures
Number of Products under Development for Solid Tumors, 2011
Products under Development for Solid Tumors – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Discovery and Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
